Paper17548498
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Nakata H and 11 others. Antimicrob Agents Chemother, 2007. Cited by 86 papers, by iCite.
Cite this record
ConductScience Library. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Papers, record 17548498. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17548498
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-HIV Agents | Major topic |
| DNA-Directed DNA Polymerase | Major topic |
| Deoxyadenosines | Major topic |
| HIV-1 | Major topic |
| Reverse Transcriptase Inhibitors | Major topic |
| CD4-Positive T-Lymphocytes | |
| Cells, Cultured | |
| Culture Media | |
| Humans | |
| Microbial Sensitivity Tests | |
| Tritium | |
| Zidovudine |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI038204 | NIAID NIH HHS | United States | R01AI038204 | PubMed and NIH | NIH RePORTER |
| R56 AI038204 | NIAID NIH HHS | United States | R01AI038204 | PubMed and NIH | NIH RePORTER |
| Intramural NIH HHS | United States | PubMed | PubMed | ||
| R01 GM049551 | NIGMS NIH HHS | United States | R01GM049551 | PubMed and NIH | NIH RePORTER |
| AI38204 | NIAID NIH HHS | United States | R01AI038204 | PubMed and NIH | NIH RePORTER |
| GM49551 | NIGMS NIH HHS | United States | R01GM049551 | PubMed and NIH | NIH RePORTER |
| Z01SC006738 | NIH | NIH RePORTER |
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10570065 | Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine). | Mol Pharmacol | 1999 | https://conductscience.org/library/papers/10570065 | PubMed |
| 2 | 17371811 | A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17371811 | PubMed |
| 3 | 11302824 | 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11302824 | PubMed |
| 4 | 11454872 | Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. | J Biol Chem | 2001 | https://conductscience.org/library/papers/11454872 | PubMed |
| 5 | 11594679 | The molecular basis of inhibition and toxicity of modified cytosine analogues targetting HIV-1 reverse transcriptase. | Antivir Chem Chemother | 2001 | https://conductscience.org/library/papers/11594679 | PubMed |
| 6 | 11692304 | Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. | Clin Infect Dis | 2001 | https://conductscience.org/library/papers/11692304 | PubMed |
| 7 | 11773409 | A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. | J Virol | 2002 | https://conductscience.org/library/papers/11773409 | PubMed |
| 8 | 12119605 | Strategies in the design of antiviral drugs. | Nat Rev Drug Discov | 2002 | https://conductscience.org/library/papers/12119605 | PubMed |
| 9 | 12455229 | 4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants. | Curr Drug Targets Infect Disord | 2001 | https://conductscience.org/library/papers/12455229 | PubMed |
| 10 | 14506019 | Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/14506019 | PubMed |
| 11 | 15035022 | HIV-1 dynamics in vivo: implications for therapy. | Nat Rev Microbiol | 2003 | https://conductscience.org/library/papers/15035022 | PubMed |
| 12 | 15199316 | HIV-associated neuromuscular weakness syndrome. | AIDS | 2004 | https://conductscience.org/library/papers/15199316 | PubMed |
| 13 | 15163657 | A long-term latent reservoir for HIV-1: discovery and clinical implications. | J Antimicrob Chemother | 2004 | https://conductscience.org/library/papers/15163657 | PubMed |
| 14 | 15238771 | SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. | AIDS | 2004 | https://conductscience.org/library/papers/15238771 | PubMed |
| 15 | 15456247 | A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides. | J Med Chem | 2004 | https://conductscience.org/library/papers/15456247 | PubMed |
| 16 | 2430286 | Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. | Proc Natl Acad Sci U S A | 1986 | https://conductscience.org/library/papers/2430286 | PubMed |
| 17 | 2109183 | 2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine. | Mol Pharmacol | 1990 | https://conductscience.org/library/papers/2109183 | PubMed |
| 18 | 1730594 | Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus. | J Biol Chem | 1992 | https://conductscience.org/library/papers/1730594 | PubMed |
| 19 | 8387546 | Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. | J Clin Invest | 1993 | https://conductscience.org/library/papers/8387546 | PubMed |
| 20 | 7685186 | Selective action of 4'-azidothymidine triphosphate on reverse transcriptase of human immunodeficiency virus type 1 and human DNA polymerases alpha and beta. | Biochemistry | 1993 | https://conductscience.org/library/papers/7685186 | PubMed |
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40042304 | Pharmacokinetics of islatravir in participants with moderate hepatic impairment. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40042304 | PubMed |
| 39831159 | An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. | PNAS Nexus | 2025 | https://conductscience.org/library/papers/39831159 | PubMed |
| 39105584 | Intracellular islatravir-triphosphate half-life supports extended dosing intervals. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/39105584 | PubMed |
| 36933835 | A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes. | Virus Res | 2023 | https://conductscience.org/library/papers/36933835 | PubMed |
| 36841831 | Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. | Nat Commun | 2023 | https://conductscience.org/library/papers/36841831 | PubMed |
| 36346229 | Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36346229 | PubMed |
| 35847492 | Approved HIV reverse transcriptase inhibitors in the past decade. | Acta Pharm Sin B | 2022 | https://conductscience.org/library/papers/35847492 | PubMed |
| 35475215 | A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. | Cell Rep Methods | 2021 | https://conductscience.org/library/papers/35475215 | PubMed |
| 34676683 | Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate. | Clin Pharmacol Drug Dev | 2021 | https://conductscience.org/library/papers/34676683 | PubMed |
| 34516245 | Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/34516245 | PubMed |
| 34463432 | Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV. | Clin Transl Sci | 2021 | https://conductscience.org/library/papers/34463432 | PubMed |
| 33333207 | Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. | J Hepatol | 2021 | https://conductscience.org/library/papers/33333207 | PubMed |
| 32737197 | Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery. | J Biol Chem | 2020 | https://conductscience.org/library/papers/32737197 | PubMed |
| 32084506 | 7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. | Antiviral Res | 2020 | https://conductscience.org/library/papers/32084506 | PubMed |
| 32080249 | Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine. | Sci Rep | 2020 | https://conductscience.org/library/papers/32080249 | PubMed |
| 31992748 | Potent inhibition of HIV replication in primary human cells by novel synthetic polyketides inspired by Aureothin. | Sci Rep | 2020 | https://conductscience.org/library/papers/31992748 | PubMed |
| 31774001 | Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. | Expert Rev Clin Pharmacol | 2019 | https://conductscience.org/library/papers/31774001 | PubMed |
| 31424371 | Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. | Curr Top Med Chem | 2019 | https://conductscience.org/library/papers/31424371 | PubMed |
| 31085520 | Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31085520 | PubMed |
| 30670420 | CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30670420 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17548498
GET https://conductscience.org/api/papers/v1/17548498/references?page=2